Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALVR 109

Next Previous
X
Search
Drug Profile

ALVR 109

Alternative Names: ALVR-109; SARS-CoV-2-specific T cell therapy; SARS-CoV2-specific T cells - AlloVir; SARS-CoVSTs - AlloVir

Latest Information Update: 28 Dec 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer AlloVir; Baylor College of Medicine
  • Class Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for phase-I development in COVID-2019-infections in USA (IV, Infusion)
  • 31 Dec 2022 Allovir has patents pending for ALVR 109 in USA, Canada, Europe, Japan, and Taiwan
  • 21 Dec 2021 AlloVir in collaboration with the Baylor College of Medicine terminates a phase-I trial in COVID-2019 infections in USA (IV) (NCT04401410)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top